Business & regional news

First procedure performed at Axia Women’s Health by Dr. Vincent R. Lucente

Heart Rhythm 2026: Real-world outcomes reinforce Aurora EV-ICD system as a reliable option for indicated patients requiring protection from dangerously fast heart rhythms

Post-approval study’s primary cohort shows 70.2% target lesion primary patency consistent with pivotal randomized controlled trial results in a challenging population¹

Company honored for creating the world's first Adaptive deep brain stimulation (aDBS) system for people with Parkinson's

EMBRACE trial to study renal denervation with the Symplicity Spyral™ system and percutaneous coronary intervention (PCI) in the same procedure In SPYRAL HTN ON and OFF MED trials, patients...

Empowering endoscopists with meaningful insights

Milestone expands patient access to the first and most studied renal denervation therapy for hypertension.

Infuse™ is the only PMA-approved growth factor bone graft indicated for ALIF, OLIF, and TLIF

University of Colorado selected as a strategic academic partner given the strength of the capabilities to advance disruptive innovation in health care

Pharmacy Benefit agreements expand portfolio coverage to simplify access for eligible customers and providers

Results from Australia, Japan and Hong Kong highlight the potential impact across healthcare systems in the Asia-Pacific region

Onyx™ 18, 34 Liquid Embolic System offers step forward in treatment options for cSDH

Medtronic also announced completion of enrollment in SPYRAL AFFIRM, which aims to build robust real-world evidence across traditionally underserved patient populations

Avalus Ultra valve expands Medtronic Cardiac Surgery’s portfolio of
cardiac surgical innovations

Findings highlight the potential of new investigational waveforms for the all-in-one mapping and dual-energy ablation system in advancing treatment for ventricular arrhythmia patients

Backed by exceptional clinical outcomes, the Neuroguard IEP™ System’s unique 3-in-1 design provides enhanced embolic protection when it matters most.1-5, † Medtronic, a global leader in...

Dr. Arthur brings more than 20 years of experience as a practicing neurosurgeon and a commitment to innovation, patient safety, and improving stroke care outcomes

London office expansion underlines Medtronic’s commitment to fostering cross-industry collaboration, contributing to ambitions of the NHS 10-Year Health Plan and driving surgical innovation.

The pivotal Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) trial demonstrates global clinical effectiveness, long-term safety, and patient preference

Japan is now the 77th country to receive regulatory approval for the Symplicity Spyral Renal Denervation System

Albany Medical Center performs first patient procedure in clinical trial for use of peripheral vasculature liquid embolization for active arterial hemorrhage

Medtronic advances pipeline with update on multi-organ denervation study and additional data recently presented at EuroPCR 2025

Large, international registry designed to expand real-world data for Symplicity blood pressure procedure for uncontrolled hypertension

Medtronic, a global leader in healthcare technology, is proud to announce that it has been honored with the 2025 MedTech Breakthrough Award for 'Best Overall Medical Device Solution' for its...

Medtronic, a global leader in healthcare technology, announced today that it has received CE (Conformité Européenne) Mark approval for several expanded indications for the treatment of coronary...

With its advanced multi-beat hemodynamic algorithm, the Argos™ monitor expands the parameters in the Medtronic perioperative portfolio

New investigational energy waveforms created specifically to target ventricular arrhythmias

Ventricular arrhythmia research will provide important clinical evidence using a new technology for patient population in need of new treatment options

Data from the largest study comparing drug-coated balloons presented as a late-breaking clinical trial at Cardiovascular Research Technologies 2025

The company will present clinical evidence at ATTD exploring challenges faced by women living with type 1 diabetes, from menstruation to pregestational diabetes

Taking the patient experience to the next stage

St. Francis Hospital in New York performs the first patient procedure in clinical trial for coronary artery disease

Study shows 67% mean reduction in Low-back Visual Analog Scale (VAS) pain score at 12 months; 87% of subjects had meaningful improvements in three or more quality of life (QoL) domains

Data to be presented at the North American Neuromodulation Society (NANS) Annual Meeting 2025; In all, Medtronic to highlight 22 poster and oral scientific data presentations

Data include durability of PulseSelect integrated with the Affera system, same day discharge and zero fluoroscopy with Affera and Sphere-9™ Catheter

Highlights underscore positive momentum of commercial launch of Affera in the U.S. and continued strong adoption of PulseSelect globally

Real-world use continues to demonstrate safety, efficacy and efficiency of both PFA technologies amid global expansion

Agreement includes option to acquire the company

Harmony™ Transcatheter Pulmonary Valve system approval expands minimally invasive treatment options for patients with congenital heart disease across European Union

Two data releases at London Valves 2024 build on Evolut’s legacy of valve design and performance: Optimize PRO study demonstrates improved procedure efficiencies and valve performance Pooled...

New data from Australia, Japan, India, Singapore, Hong Kong, and South Korea demonstrates the MiniMed™ 780G is driving consistent clinical outcomes in diabetes management.

Comparative data and systematic literature review released at VIVA 2024 show breadth and depth of data supporting atherectomy as a treatment for peripheral arterial disease

The VT research will provide important clinical evidence in an underserved patient population

Global expansion of the Avalus Ultra valve continues in Western Europe while company highlights robust, innovative Cardiac Surgery portfolio at EACTS in Lisbon

Company recognized among top 52 global companies making positive social impact through core business strategy

ADAPT-PD trial methods and preliminary data published in npj Parkinson’s disease

The company will present clinical evidence in young children, pregnancy and type 2 diabetes*

Post-market data collection will add real-world experience to established safety, efficacy, and efficiency evidence profile

New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.

Medtronic will present the latest data on its MiniMed™ 780G insulin pump and showcase the company’s latest CareLink™ experience launching globally this month

Medtronic, a global leader in medical technology, announced today that it has received U.S. FDA Breakthrough Device designation for Infuse™ bone graft with an intervertebral fusion device and a...

The company is pursuing hernia and gynecology indications along with urology as it progresses plans to bring choice in robotic surgery technology and partnership to the U.S. Medtronic, a global...

Preliminary findings of the first and only head-to-head trial comparing standard-of-care CT-guided biopsy with electromagnetic navigation bronchoscopy (ENB) for the diagnosis of lung nodules demonstrate non-inferiority and fewer complications when using ENB

Symplicity Spyral is the first renal denervation technology to be approved by the National Medical Products Administration; new, innovative, minimally invasive procedure uses radiofrequency energy to help reduce high blood pressure

Medtronic, the global leader in healthcare technology, today announced the release of important clinical outcomes in two leading transcatheter valve therapies. The results for these studies were...

Study shows the investigational use of the MiniMed™ 780G system improved glycemic control during pregnancy. Medtronic, a global leader in healthcare technology, today announced the results of...

Next-generation Avalus Ultra valve is Medtronic’s most advanced surgical aortic tissue valve built on 10 years of clinical experience with the Avalus™ valve

Medtronic today announced it received a license from Health Canada for its Symplicity Spyral™ multi-electrode Renal Denervation (RDN) System. This is indicated for the management of essential...

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Medtronic, a global leader in medical technology, announced today the launch of the new UNiD™ ePRO service in the United States. This solution will change the way patient outcomes are collected...

Medtronic will unveil the MiniMed™ 780G system with Simplera Sync™, a new disposable, all-in-one sensor.*

Physician feedback confirms clinical evidence: safe, efficient, and effective treatment offers most versatile new option for atrial fibrillation

86% of subjects preferred closed-loop SCS in a multicenter, randomized, crossover, single blind study of Medtronic’s investigational closed-loop SCS system at one month

24-month European RCT data demonstrates long-term superiority of DTM™ SCS compared with conventional medical management (CMM) for indicated chronic back pain patients not eligible for spine surgery

The next-generation DBS technology is now available in a rechargeable option

Simplicity, efficiency, efficacy with unmatched safety data to set a new standard in catheter ablation

NOVA Study: On-label, prospective, multicenter, randomized controlled trial compared DTM™ SCS to conventional spinal cord stimulation

Next-Gen Evolut FX TAVI system enhances procedure ease-of-use, visualization, and predictability

• Improved survival with ICD therapy: nearly 25% lower risk of death in indicated patients receiving an ICD vs. no ICD
• ICDs confer additional long-term benefits after initial device replacement

40-site pilot program across US, UK, and Europe aims to introduce cutting edge AI solutions into the clinical environment to improve patient care and efficiency

Orders will be processed immediately and shipments will start in the coming weeks

SCAI 2023 Scientific Sessions: Harmony™ Transcatheter Pulmonary Valve System Demonstrates Strong Clinical and Hemodynamic Outcomes at Two Years

Heart Rhythm 2023: Late-breaking analysis of the PULSED AF Trial reveals first of its kind significant, meaningful quality of life improvements and healthcare utilization benefits of the PulseSelect Pulsed Field Ablation System

ACC.23/WCC Late-Breaking Clinical Trial: Evolut™ is only TAVR to show excellent outcomes in low-risk patients at 3 years

CRT 2023 Late-Breaking Data: CoreValve/Evolut™ platform demonstrates significantly lower bioprosthetic valve dysfunction compared to surgery at five years

ADVANCE Trial compares sac regression in the Medtronic Endurant™ II/IIs stent graft system and the Gore® Excluder®* AAA Device Family systems

Late-breaking clinical presentations at VIVA show IN.PACT™ Admiral™ drug-coated PTA balloon catheter outperforms bare metal stents; maintains performance in real-world setting

Study data show clinically meaningful impact on quality of life and disease severity, even in the most complex patients

Medtronic announced today that it recently received CE mark for its Radiant™ balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the...

TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...